Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial

Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have rise...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Danyal Ibrahim, Latha Dulipsingh, Lisa Zapatka, Reginald Eadie, Rebecca Crowell, Kendra Williams, Dorothy B. Wakefield, Lisa Cook, Jennifer Puff, Syed A. Hussain
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2020-09-01
coleção:	Infectious Diseases and Therapy
Assuntos:	Adult respiratory distress syndrome COVID-19 COVID-19 serotherapy Hospital mortality Length of stay Phase II clinical trial
Acesso em linha:	https://doi.org/10.1007/s40121-020-00341-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!